IL-7/alpha IL-7 mAb M25 immunocomplexes expand CD8(+) T cells but paradoxically abrogate the antitumor activity of CTLA-4 and PD-1 blockage

0531980 - MBÚ 2021 RIV GB eng J - Článek v odborném periodiku
Hraboš, Dominik - Hnízdilová, Tereza - Tomala, Jakub - Uhlík, J. - Kovář, Marek
IL-7/alpha IL-7 mAb M25 immunocomplexes expand CD8(+) T cells but paradoxically abrogate the antitumor activity of CTLA-4 and PD-1 blockage.
Cytokine. Roč. 133, SEP 2020 (2020), č. článku 155174. ISSN 1043-4666. E-ISSN 1096-0023
Grant CEP: GA ČR(CZ) GA18-12973S
Institucionální podpora: RVO:61388971
Klíčová slova: IL-7 immunocomplexes * CTLA-4 * PD-1
Obor OECD: Microbiology
Impakt faktor: 3.861, rok: 2020
Způsob publikování: Open access
https://www.sciencedirect.com/science/article/pii/S1043466620301903

Supraphysiological levels of IL-7 induce increase counts of pre-B cells, naive T cells and memory phenotype CD8(+) T cells. Immunocomplexes of IL-7 and alpha IL-7 mAb M25 (IL-7/M25) were described as IL-7 superagonist in vivo. Thus, treatment of mice with IL-7/M25 remarkably increases the size of the T cell pool. We decided to use IL-7/M25 in order to expand the T cell population prior to the administration of alpha CTLA-4 and alpha PD-1 mAbs in tumor-bearing mice and in turn boost the immunotherapy based on a combination of CTLA-4 and PD-1 blockage. We found that just four doses of IL-7/M25 increased the absolute numbers of splenocytes approximately fivefold and significantly shifted the CD4(+):CD8(+) T cell ratio in favor of CD8(+) T cells. There was also a substantive increase in relative counts of memory phenotype CD8(+) T cells (approximately threefold) within CD8(+) T cells but a significant decrease (approximately 30%) in relative counts of Treg cells within CD4(+) T cells. All these data suggest that IL-7/M25 offer a suitable approach to potentiate tumor immunotherapy through CTLA-4 and PD-1 blockage. Unexpectedly, IL-7/M25 significantly abrogated the antitumor activity of alpha CTLA-4 plus alpha PD-1 mAbs in the following mouse tumor models: MC-38 and CT26 colon carcinoma and B16F10 melanoma. This paradoxical effect of IL-7/M25 on the antitumor activity of CTLA-4 and PD-1 blockage was not mediated via either increased levels of IL-10 or TGF-beta in the sera or increased counts of IL-10-producing B or T cells in the spleen of mice injected with IL-7/M25. Thus, our work shows that caution should be exercised when combining two immunotherapy approaches together.
Trvalý link: http://hdl.handle.net/11104/0310597